...fluoro-sorafenib, regorafenib (BAY 73-4506, DAST Inhibitor) Sutent, sunitinib (SU11248) Tagrisso (Brand), AZD9291, osimertinib (Generic), Tagrisso (Other) Tasigna, nilotinib (AMN107) Vidaza...

...NYSE:NVS; SIX:NOVN) for myelofibrosis; Gilotrif afatinib from Boehringer Ingelheim GmbH (Ingelheim, Germany) for NSCLC; Tasigna nilotinib...

...Basel, Switzerland Business: Pharmaceuticals Jaime De Leon Gilenya, Imusera, fingolimod (FTY720, TDI-132) Kymriah, tisagenlecleucel (CTL019, cart-19, tisagenlecleucel-t) Tasigna, nilotinib (AMN107) Novartis...

...figures provided by FactSet. Jaime De Leon Gilenya, Imusera, fingolimod (FTY720, TDI-132) Kymriah, tisagenlecleucel (CTL019, cart-19, tisagenlecleucel-t) Tasigna, nilotinib (AMN107) Novartis...

...involved drugs that did not have an ETASU -- Afinitor everolimus, Exjade deferasirox and Tasigna nilotinib...
...ICL670 (Compound #), deferasirox (Informal), Exjade (Other) Imnovid, Pomalyst, pomalidomide (CC-4047) Revlimid, lenalidomide (cdc 501, CC-5013) Tasigna, nilotinib (AMN107) Thalomid...

...involved drugs that did not have an ETASU -- Afinitor everolimus, Exjade deferasirox and Tasigna nilotinib...
...ICL670 (Compound #), deferasirox (Informal), Exjade (Other) Imnovid, Pomalyst, pomalidomide (CC-4047) Revlimid, lenalidomide (cdc 501, CC-5013) Tasigna, nilotinib (AMN107) Thalomid...

...AG’s leukemia drug Tasigna nilotinib modestly improved motor symptoms and cognitive performance in PD patients. Tasigna...
...in the indication. Kim noted 1ST-102 has a hundred- to thousand-fold better BBB penetration than Tasigna...

...FDA updated the label of Tasigna nilotinib from Novartis AG (NYSE:NVS; SIX:NOVN) to reflect that some...
...to treat Philadelphia chromosome-positive (Ph+) CML in chronic phase. At 96 weeks after stopping treatment, Tasigna...
...CML in chronic phase. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Tasigna nilotinib Business: Cancer Allison Johnson nilotinib Tasigna Novartis...

...FDA updated the label of Tasigna nilotinib from Novartis AG (NYSE:NVS; SIX:NOVN) to reflect that some...
...to treat Philadelphia chromosome-positive (Ph+) CML in chronic phase. At 96 weeks after stopping treatment, Tasigna...
...Tasigna as first- and second-line treatment for pediatric patients with Ph+ CML in chronic phase. Allison Johnson nilotinib Tasigna Novartis...

...Novartis AG (NYSE:NVS; SIX:NOVN) said the European Commission approved a label expansion for Tasigna nilotinib to...
...Tasigna is a BCR-ABL tyrosine kinase (BCR-ABL) inhibitor. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Tasigna...
...tyrosine kinase (BCR-ABL) inhibitor. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Tasigna nilotinib Business: Cancer Alex Himes nilotinib Tasigna Novartis...